Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageThe genome is composed of 3 billion “letters”, or base pairs, of DNA. The exome is a portion of the genome that encodes proteins, which are involved in many different types of cellular functions. Changes in DNA can change the way proteins are formed or utilized by the cell, potentially causing disease. When patients present with complex issues, a genetic diagnosis may be available, but a traditional genetic panel test may be too narrow to identify the cause.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Business segments
Q1 2026 · $101.7MThe company’s own SEC segment disclosure.
- Diagnostic Test Third Party Insurance$84.9M84%
- Diagnostic Test Institutional Customers$15.5M15%
- Product And Service Other$955.0K1%
- Diagnostic Test Self Pay$286.0K0%
GeneDx Holdings Corp. (WGS) reported revenue of $102M in Q1 2026 (quarter ended March 31, 2026), up 17% from the same quarter a year earlier. That came with a gross margin of 67% and net loss of $63M. For the full year FY2025, revenue was $428M (+40% year on year) and net income −$21M. Its largest product in 2026-Q1 was Diagnostic Test Third Party Insurance at $85M, 84% of the disclosed total, just ahead of Diagnostic Test Institutional Customers at 15%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #28 of 29 by Smart Score